The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 101-108

  Benad, Peggy ^a   Rauner, Martina ^a   Rachner, Tilman D ^a   Hofbauer, Lorenz C ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

Breast cancer; RU 486; WNT1

Indexed keywords

BETA ACTIN; GLUCOCORTICOID RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MIFEPRISTONE; PROGESTERONE RECEPTOR; WNT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CELL STRAIN T 47D; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MIFEPRISTONE; RECEPTORS, PROGESTERONE; WNT SIGNALING PATHWAY; WNT1 PROTEIN;

EID: 80053318512     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.006     Document Type: Article

References (31)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46(4):765-781.
2. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362(9382):419-427.
3. Beleut M., Rajaram R.D., Caikovski M., Ayyanan A., Germano D., Choi Y., et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. USA 2010, 107(7):2989-2994.
4. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468(7320):103-107.
5. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468(7320):98-102.
6. Bakker G.H., Setyono-Han B., Portengen H., De Jong F.H., Foekens J.A., Klijn J.G. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 1990, 37(6):789-794.
7. Gaddy V.T., Barrett J.T., Delk J.N., Kallab A.M., Porter A.G., Schoenlein P.V. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin. Cancer Res. 2004, 10(15):5215-5225.
8. Klijn J.G., de Jong F.H., Bakker G.H., Lamberts S.W., Rodenburg C.J., Alexieva-Figusch J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989, 49(11):2851-2856.
9. Klijn J.G., Setyono-Han B., Foekens J.A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 2000, 65(10-11):825-830.
10. Sarkar N.N. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002, 101(2):113-120.
11. Engman M., Skoog L., Soderqvist G., Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum. Reprod. 2008, 23(9):2072-2079.
12. Brisken C., Heineman A., Chavarria T., Elenbaas B., Tan J., Dey S.K., et al. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000, 14(6):650-654.
13. Faivre E.J., Lange C.A. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol. Cell. Biol. 2007, 27(2):466-480.
14. Lin S.Y., Xia W., Wang J.C., Kwong K.Y., Spohn B., Wen Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97(8):4262-4266.
15. Tsukamoto A.S., Grosschedl R., Guzman R.C., Parslow T., Varmus H.E. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988, 55(4):619-625.
16. Wieczorek M., Paczkowska A., Guzenda P., Majorek M., Bednarek A.K., Lamparska-Przybysz M. Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells. Cancer Biol. Ther. 2008, 7(2):268-274.
17. Kumar R., Balasenthil S., Pakala S.B., Rayala S.K., Sahin A.A., Ohshiro K. Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res. 2010, 70(16):6598-6608.
18. Milovanovic T., Planutis K., Nguyen A., Marsh J.L., Lin F., Hope C., et al. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int. J. Oncol. 2004, 25(5):1337-1342.
19. Watanabe O., Imamura H., Shimizu T., Kinoshita J., Okabe T., Hirano A., et al. Expression of twist and wnt in human breast cancer. Anticancer Res. 2004, 24(6):3851-3856.
20. Wong S.C., Lo S.F., Lee K.C., Yam J.W., Chan J.K., Wendy Hsiao W.L. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours. J. Pathol. 2002, 196(2):145-153.
21. Brown A.M. Wnt signaling in breast cancer: have we come full circle?. Breast Cancer Res. 2001, 3(6):351-355.
22. Turashvili G., Bouchal J., Burkadze G., Kolar Z. Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 2006, 73(5):213-223.
23. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 2004, 83(3):249-289.
24. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10(6):515-527.
25. Bombonati A., Sgroi D.C. The molecular pathology of breast cancer progression. J. Pathol. 2010, 223(2):307-317.
26. Benhaj K., Akcali K.C., Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol. Rep. 2006, 15(3):701-707.
27. Lustig B., Jerchow B., Sachs M., Weiler S., Pietsch T., Karsten U., et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol. 2002, 22(4):1184-1193.
28. Bardon S., Vignon F., Chalbos D., Rochefort H. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. J. Clin. Endocrinol. Metab. 1985, 60(4):692-697.
29. Bardon S., Vignon F., Montcourrier P., Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res. 1987, 47(5):1441-1448.
30. Gill P.G., Vignon F., Bardon S., Derocq D., Rochefort H. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res. Treat. 1987, 10(1):37-45.
31. Schaff E.A. Mifepristone: ten years later. Contraception 2010, 81(1):1-7.